NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 199 filers reported holding NEKTAR THERAPEUTICS in Q4 2016. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $58,385 | -78.0% | 83,063 | +68.5% | 0.00% | – |
| Q1 2022 | $265,000 | -39.8% | 49,307 | +51.2% | 0.00% | – |
| Q4 2021 | $440,000 | -81.2% | 32,611 | -75.0% | 0.00% | -100.0% |
| Q3 2021 | $2,340,000 | +218.4% | 130,292 | +201.2% | 0.01% | +166.7% |
| Q4 2020 | $735,000 | +260.3% | 43,256 | +391.5% | 0.00% | +50.0% |
| Q2 2020 | $204,000 | -84.2% | 8,800 | -87.8% | 0.00% | -80.0% |
| Q1 2020 | $1,290,000 | +36.7% | 72,224 | +65.3% | 0.01% | +42.9% |
| Q4 2019 | $944,000 | -28.1% | 43,686 | -39.4% | 0.01% | -36.4% |
| Q3 2019 | $1,313,000 | +223.4% | 72,100 | +531.4% | 0.01% | +266.7% |
| Q2 2019 | $406,000 | +18.4% | 11,419 | +12.0% | 0.00% | +50.0% |
| Q1 2019 | $343,000 | +12.8% | 10,198 | +10.0% | 0.00% | 0.0% |
| Q4 2018 | $304,000 | -87.8% | 9,268 | -77.4% | 0.00% | -85.7% |
| Q3 2018 | $2,500,000 | +130.2% | 41,006 | +84.4% | 0.01% | +133.3% |
| Q2 2018 | $1,086,000 | -46.8% | 22,234 | +15.8% | 0.01% | -50.0% |
| Q1 2018 | $2,040,000 | +22.3% | 19,200 | -31.2% | 0.01% | +50.0% |
| Q4 2017 | $1,668,000 | +277.4% | 27,887 | +51.5% | 0.01% | +300.0% |
| Q3 2017 | $442,000 | +55.6% | 18,412 | +27.5% | 0.00% | +100.0% |
| Q2 2017 | $284,000 | -68.6% | 14,438 | -62.5% | 0.00% | -83.3% |
| Q1 2017 | $904,000 | +173.1% | 38,551 | +43.1% | 0.01% | +200.0% |
| Q4 2016 | $331,000 | +101.8% | 26,940 | +183.3% | 0.00% | – |
| Q3 2016 | $164,000 | +95.2% | 9,510 | +61.2% | 0.00% | – |
| Q2 2016 | $84,000 | -75.6% | 5,900 | -76.4% | 0.00% | -100.0% |
| Q1 2016 | $344,000 | -2.3% | 24,956 | +19.4% | 0.00% | +33.3% |
| Q4 2015 | $352,000 | +11633.3% | 20,904 | +6868.0% | 0.00% | – |
| Q3 2015 | $3,000 | -86.4% | 300 | -82.4% | 0.00% | – |
| Q2 2015 | $22,000 | -53.2% | 1,700 | -59.4% | 0.00% | – |
| Q1 2015 | $47,000 | +6.8% | 4,190 | +48.5% | 0.00% | – |
| Q4 2014 | $44,000 | -52.2% | 2,822 | -63.4% | 0.00% | – |
| Q3 2014 | $92,000 | -70.8% | 7,717 | -68.7% | 0.00% | -100.0% |
| Q2 2014 | $315,000 | +707.7% | 24,652 | +670.4% | 0.00% | – |
| Q1 2014 | $39,000 | – | 3,200 | +319900.0% | 0.00% | – |
| Q4 2013 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |